Research interests
Type 1 Diabetes
Type 2 Diabetes
Beta-cell dysfunction
Drug development and delivery
Islet Transplants
Units taught
Doctor of Medicine, HME911 Human Biology Topic Coordinator
Awards
2021 Institute for Mental and Physical Health and Clinical Translation (IMPACT) Outstanding Service Award
2017 Deakin University Faculty of Health Award for outstanding leadership
2012JDRF/Maquarie Group Foundation Early-Stage Researcher Travel Grant
2012 CASS Foundation Early Career Researcher Award
2009 Travel Scholarship, Recent Advances in Beta Cell Biology, International Diabetes Federation and University of Toronto
2006 Travel Scholarship, Australian Diabetes Society
2005 Pincus-Taft Young Investigator Award (Awarded by the Australian Diabetes Society)
2005 Travel Scholarship, Australian Diabetes Society
2005 Sanofi aventis Diabetes Partnership Young Investigator Award: Travel Grant for American Diabetes Association Annual Scientific Meeting 2005
2004 Travel Scholarship, Australian Diabetes Society
2003-2007 Australian Postgraduate Award (Scholarship)
2003 Travel Scholarship, Australian Diabetes Society
Projects
Dr. Aston-Mourney has several projects underway focusing on the insulin-secreting beta cells of the pancreas and their dysfunction in diabetes.
Currently accepting expressions of interest from prospective PhD and Honours students.
Publications
Advanced Glycation End-Products and Their Effects on Gut Health
K Phuong-Nguyen, B McNeill, K Aston-Mourney, L Rivera
(2023), Vol. 15, pp. 405-405, Nutrients, Switzerland, C1
S Sithara, T Crowley, K Walder, K Aston-Mourney
(2023), Vol. 15, pp. 2165368-, Islets, United States, C1
R Li, Q Zhou, M Tai, K Ashton-Mourney, M Harty, A Rifai, C Parish, D Nisbet, S Zhong, R Williams
(2023), Vol. 9, pp. 1-23, Gels, Basel, Switzerland, C1-1
Ramasamy Aarthy, Kathryn Aston-Mourney, Anandakumar Amutha, Antonina Mikocka-Walus, Ranjit Anjana, Ranjit Unnikrishnan, Saravanan Jebarani, Ulagamathesan Venkatesan, Sundaramoorthy Gopi, Venkatesan Radha, Viswanathan Mohan
(2023), pp. 1-7, Primary Care Diabetes, Amsterdam, The Netherlands, C1
R Aarthy, K Aston-Mourney, A Amutha, A Mikocka-Walus, R Anjana, R Unnikrishnan, S Jebarani, U Venkatesan, S Gopi, V Radha, V Mohan
(2023), Vol. 13, pp. 1-9, Scientific Reports, Berlin, Germany, C1
W Naser, S Maymand, L Rivera, T Connor, C Liongue, C Smith, K Aston-Mourney, D McCulloch, S McGee, A Ward
(2022), Vol. 36, pp. 1-15, FASEB Journal, London, Eng., C1
K Aston-Mourney, J McLeod, L Rivera, B McNeill, D Baldi
(2022), Vol. 22, BMC Medical Education, C1
R Aarthy, K Aston-Mourney, A Mikocka-Walus, V Radha, A Amutha, R Anjana, R Unnikrishnan, V Mohan
(2021), Vol. 35, Journal of Diabetes and its Complications, United States, C1
Copper Ionophores as Novel Antiobesity Therapeutics
P Meggyesy, S Masaldan, S Clatworthy, I Volitakis, D Eyckens, K Aston-Mourney, M Cater
(2020), Vol. 25, Molecules (Basel, Switzerland), Switzerland, C1
Class IIa HDACs do not influence beta-cell function under normal or high glucose conditions
J McCann, M Ellis, S McGee, K Aston-Mourney
(2019), Vol. 11, pp. 112-118, Islets, United States, C1
Metformin, beta-cell development, and novel processes following beta-cell ablation in zebrafish
G Wyett, Y Gibert, M Ellis, H Castillo, Jan Kaslin, K Aston-Mourney
(2018), Vol. 59, pp. 419-425, Endocrine, United States, C1-1
APP deficiency results in resistance to obesity but impairs glucose tolerance upon high fat feeding
J Czeczor, A Genders, K Aston-Mourney, T Connor, L Hall, K Hasebe, M Ellis, K De Jong, D Henstridge, P Meikle, M Febbraio, K Walder, S McGee
(2018), Vol. 237, pp. 311-322, Journal of Endocrinology, England, C1
Gene expression signature: A powerful approach for drug discovery in diabetes
S Sithara, T Crowley, K Walder, K Aston-Mourney
(2017), Vol. 232, pp. R131-R139, Journal of Endocrinology, England, C1
Scriptaid enhances skeletal muscle insulin action and cardiac function in obese mice
V Gaur, T Connor, K Venardos, D Henstridge, S Martin, C Swinton, S Morrison, K Aston-Mourney, S Gehrig, R van Ewijk, G Lynch, M Febbraio, G Steinberg, M Hargreaves, K Walder, S McGee
(2017), Vol. 19, pp. 936-943, Diabetes, Obesity and Metabolism, England, C1
B Hayward, J Molero, K Windmill, A Sanigorski, J Weir, N McRae, K Aston-Mourney, B Osborne, B Liao, K Walder, P Meikle, N Konstantopoulos, C Schmitz-Peiffer
(2016), Vol. 124, pp. 602-612, Experimental and Clinical Endocrinology and Diabetes, Germany, C1
K Aston-Mourney, S Subramanian, S Zraika, T Samarasekera, D Meier, L Goldstein, R Hull
(2013), Vol. 305, American Journal of Physiology: Endocrinology and Metabolism, Bethesda, MD, C1
Adipocytokines as features of the metabolic syndrome determined using confirmatory factor analysis
M Smits, P Woudstra, K Utzschneider, J Tong, F Gerchman, M Faulenbach, D Carr, K Aston-Mourney, A Chait, R Knopp, J Meigs, E Boyko, S Kahn
(2013), Vol. 23, pp. 415-421, Annals of Epidemiology, Amsterdam, Netherlands, C1-1
J Udayassankar, S Zraika, K Aston-Mourney, S Subramanian, B Brooks-Worrell, G Taborsky, R Hull
(2013), Vol. 45, pp. 574-579, Transplantation Proceedings, New York, NY, C1-1
Matrix Metalloproteinase-9 reduces islet amyloid formation by degrading islet amyloid polypeptide
K Aston-Mourney, S Zraika, J Udayasankar, S Subramanian, P Green, S Kahn, R Hull
(2013), Vol. 288, pp. 3553-3559, The journal of biological chemistry, Bethesda, Maryland, C1
S Subramanian, R Hull, S Zraika, K Aston-Mourney, J Udayasankar, S Kahn
(2012), Vol. 55, pp. 166-174, Diabetologia, Heidelberg , Germany, C1-1
B-cell loss and B-cell apoptosis in human type 2 diabetes are related to islet amyloid deposition
C Jurgens, M Toukatly, C Fligner, J Udayasankar, S Subramanian, S Zraika, K Aston-Mourney, D Carr, P Westermark, G Westermark, S Kahn, R Hull
(2011), Vol. 178, pp. 2632-2640, American journal of clinical pathology, Birmingham, Ala., C1-1
K Aston-Mourney, R Hull, S Zraika, J Udayasankar, S Subramanian, S Kahn
(2011), Vol. 54, pp. 1756-1765, Diabetologia, Heidelberg, Germany, C1-1
S Zraika, K Aston-Mourney, P Marek, R Hull, P Green, J Udayasankar, S Subramanian, D Raleigh, S Kahn
(2010), Vol. 285, pp. 18177-18183, Journal of biological chemistry, Bethesda, Md., C1-1
J Udayasankar, K Kodama, R Hull, S Zraika, K Aston-Mourney, S Subramanian, J Tong, M Faulenbach, J Vidal, S Kahn
(2009), Vol. 52, pp. 145-153, Diabetologia, Heidelberg, Germany, C1-1
S Zraika, R Hull, J Udayasankar, K Aston-Mourney, S Subramanian, R Kisilevsky, W Szarek, S Kahn
(2009), Vol. 52, pp. 626-635, Diabetologia, Heidelberg, Germany, C1-1
R Hull, S Zraika, J Udayasankar, K Aston-Mourney, S Subramanian, S Kahn
(2009), Vol. 52, pp. 1102-1111, Diabetologia, Heidelberg, Germany, C1-1
M Kebede, J Favaloro, J Gunton, D Laybutt, M Shaw, N Wong, B Fam, K Aston-Mourney, C Rantzau, A Zulli, J Proietto, S Andrikopoulos
(2008), Vol. 57, pp. 1887-1895, Diabetes, Alexandria, Va, C1-1
Too much of a good thing : why it is bad to stimulate the beta cell to secrete insulin
K Aston-Mourney, J Proietto, G Morahan, S Andrikopoulos
(2008), Vol. 51, pp. 540-545, Diabetologia, Heidelberg, Germany, C1-1
K Aston-Mourney, N Wong, M Kebede, S Zraika, L Balmer, J McMahon, B Fam, J Favaloro, J Proietto, G Morahan, S Andrikopoulos
(2007), Vol. 50, pp. 2476-2485, Diabetologia, Heidelberg, Germany, C1-1
S Zraika, K Aston-Mourney, D Laybutt, M Kebede, M Dunlop, J Proietto, S Andrikopoulos
(2006), Vol. 49, pp. 1254-1263, Diabetologia, Heidelberg, Germany, C1-1
Investigational agents that protect pancreatic islet β-cells from failure
K Aston-Mourney, J Proietto, S Andrikopoulos
(2005), Vol. 14, pp. 1241-1250, Expert opinion on investigational drugs, England, London, C1-1
S Andrikopoulos, C Massa, K Aston-Mourney, A Funkat, B Fam, R Hull, S Kahn, J Proietto
(2005), Vol. 187, pp. 45-53, Journal of endocrinology, Bristol, England, C1-1
S Kooptiwut, M Kebede, S Zraika, S Visinoni, K Aston-Mourney, J Favaloro, C Tikellis, M Thomas, J Forbes, M Cooper, M Dunlop, J Proietto, S Andrikopoulos
(2005), Vol. 35, pp. 39-48, Journal of molecular endocrinology, Bristol, England, C1-1
Funded Projects at Deakin
Australian Competitive Grants
A novel approach to target beta-cells to enhance survival and function
A/Prof Kathryn Aston-Mourney, A/Prof Sarah Shigdar, Prof Sean Mcgee
DART Grant - Research - Diabetes Australia - Victoria (Research Trust)
- 2020: $59,756
Other Public Sector Funding
MiSeq Next Generation Sequencer
A/Prof Kathryn Aston-Mourney
NHMRC - Equipment Grant (pre 2017)
- 2013: $15,000
Industry and Other Funding
JDRF Travel Grant
A/Prof Kathryn Aston-Mourney
Juvenile Diabetes Research Fund - JDRF Australia
- 2012: $3,170
HDAC Inhibition as a Potential Therapy for Preventing the Progression of Type 2 Diabetes
A/Prof Kathryn Aston-Mourney, Prof Sean Mcgee
CASS Grant - Research - The CASS Foundation Limited
- 2015: $55,000
Generation and application of a novel screening tool for the Discovery of b-cell Protective Diabetes Drugs
A/Prof Kathryn Aston-Mourney
Sir Edward Dunlop Medical Research Foundation
- 2015: $20,650
Discovery of novel therapies for type 2 diabetes
A/Prof Kathryn Aston-Mourney
Geelong Community Foundation Grant - Research
- 2015: $32,000
Other Funding Sources
CASS Travel grant - American Diabetes Foundation
A/Prof Kathryn Aston-Mourney
CASS Travel - The CASS Foundation Limited
- 2012: $3,000
Supervisions
Bhavisha Patel
Thesis entitled: Developing Targeted Therapy for ¿-cell Dysfunction in Type 2 Diabetes
Doctor of Philosophy (Medicine), School of Medicine
Smithamol Sithara
Thesis entitled: A beta-cell specific global approach for drug identification in Type 2 Diabetes
Doctor of Philosophy (Medicine), School of Medicine